Nuvectis Pharma, Inc.

NasdaqCM:NVCT Stock Report

Market Cap: US$591.1m

Nuvectis Pharma Future Growth

Future criteria checks 0/6

Nuvectis Pharma is forecast to grow earnings and revenue by 50.8% and 75.8% per annum respectively while EPS is expected to grow by 50% per annum.

Key information

50.8%

Earnings growth rate

50.01%

EPS growth rate

Biotechs earnings growth25.3%
Revenue growth rate75.8%
Future return on equityn/a
Analyst coverage

Low

Last updated06 Jul 2026

Recent future growth updates

Recent updates

Analysis Article • May 06

Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jan 09

We Think Nuvectis Pharma (NASDAQ:NVCT) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Oct 20

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 26

We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jan 06

Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Oct 03

Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 31

We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Sep 28

Nuvectis Pharma forms scientific advisory board for research and development of drugs

Nuvectis Pharma (NASDAQ:NVCT) said on Wednesday it had formed a Scientific Advisory Board that will help guide the company’s research and development strategy. The Company's pipeline includes NXP800, a clinical-stage HSF1-pathway inhibitor, and NXP900, a SRC/YES1 kinase inhibitor in IND-enabling studies.
Seeking Alpha • Aug 05

Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04

Nuvectis Pharma press release (NASDAQ:NVCT): Q2 GAAP EPS of -$0.28 misses by $0.04. Cash, cash equivalents, and short-term investments were $13.6 million as of June 30, 2022, compared to $5.7 million as of December 31, 2021. The increase of $7.9 million was primarily a result of the Company’s initial public offering in February 2022.
Seeking Alpha • Jul 27

Nuvectis Pharma declines 13%, announces $15.9M private placement

Nuvectis Pharma (NASDAQ:NVCT) enters agreements with healthcare-focused institutional and accredited investors for the issuance and sale of 1.93M shares at a price of $8.25 per share. Gross proceeds are expected to be ~$15.9M. Closing of the private placement is expected to occur on or about July 29, 2022.
Analysis Article • May 04

We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Earnings and Revenue Growth Forecasts

NasdaqCM:NVCT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20283-42N/AN/A5
12/31/2027N/A-30N/AN/A5
12/31/2026N/A-26N/AN/A5
3/31/2026N/A-30-18-18N/A
12/31/2025N/A-29-16-16N/A
9/30/2025N/A-28-14-14N/A
6/30/2025N/A-22-12-12N/A
3/31/2025N/A-20-12-12N/A
12/31/2024N/A-19-12-12N/A
9/30/2024N/A-19-14-14N/A
6/30/2024N/A-21-14-14N/A
3/31/2024N/A-22-16-16N/A
12/31/2023N/A-22-16-16N/A
9/30/2023N/A-22-16-16N/A
6/30/2023N/A-22-17-17N/A
3/31/2023N/A-20-15-15N/A
12/31/2022N/A-19-14-14N/A
9/30/2022N/A-15-11-11N/A
6/30/2022N/A-13-11-11N/A
3/31/2022N/A-16-13-13N/A
12/31/2021N/A-13-10-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NVCT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NVCT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NVCT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NVCT is forecast to have no revenue next year.

High Growth Revenue: NVCT is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NVCT's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/09 22:08
End of Day Share Price 2026/07/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Nuvectis Pharma, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joseph PantginisH.C. Wainwright & Co.
I-Eh JenLaidlaw & Company (UK) Ltd
Christopher LiuLucid Capital Markets